Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Multicenter, Open Label Phase II Clinical Study to Evaluate Infliximab in the Treatment of Patients With Severe COVID-19 Disease

NCT04922827 is registered in ClinicalTrials.gov with Jena University Hospital as lead sponsor.

NCT NCT04922827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Multicenter, Open Label Phase II Clinical Study to Evaluate Infliximab in the Treatment of Patients With Severe COVID-19 Disease
Lead sponsor
Jena University Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 18, 2021
Completion date
July 1, 2023
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19